Bayer AG: New stakes in stem cells

January 2011. Andreas Busch, responsible for Global Drug Discovery in Bayer Pharma AG (formerly Bayer HealthCare) explains why his company opted for cancer stem cells instead of pursuing regenerative medicine. A first hand account exclusively for B2Bioworld’s readers. Insights for business development with biotech companies and options for venture capital. Includes Bayer's research pipeline (as of Dec 2010).Reading time: 4 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section